Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 4.74
- Piotroski Score 5.00
- Grade Buy
- Symbol (CDXC)
- Company ChromaDex Corporation
- Price $3.80
- Changes Percentage (0.53%)
- Change $0.02
- Day Low $3.73
- Day High $3.87
- Year High $4.65
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/05/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.05
- Trailing P/E Ratio -64
- Forward P/E Ratio -64
- P/E Growth -64
- Net Income $-4,938,000
Income Statement
Quarterly
Annual
Latest News of CDXC
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
When Will ChromaDex Corporation (NASDAQ:CDXC) Turn A Profit?
ChromaDex Corporation is a bioscience company focusing on healthy aging products, with reduced losses as it approaches breakeven. Analysts predict profitability by 2025, expecting 99% annual growth. T...
By Yahoo! Finance | 2 months ago -
Here's Why We Think ChromaDex Corporation's (NASDAQ:CDXC) CEO Compensation Looks Fair
ChromaDex's shareholders have faced a 67% loss in the past three years, but the EPS has grown by 54%. CEO Rob Fried's compensation seems reasonable, with a salary below the industry median....
By Yahoo! Finance | 3 months ago
